A Phase 2 interventional study of Tasocitinib plus Methotrexate and Tofacitinib plus placebo methotrexate in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 30th largest by enrollment, is one of 5 that started in 2010, is one of 12 in phase 2, and was the 17th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 51st largest by enrollment of the 86 interventional ones that give a count, is one of 13 that started in 2010, is one of 28 in phase 2, and was the 83rd registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tasocitinib plus Methotrexate
Drug: Tofacitinib plus placebo methotrexate
Drug: Placebo tofacitinib plus Methotrexate
Drug pages: Tofacitinib · Methotrexate
Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis
Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.
Time frame: Month 3
Change From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema
Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0-3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.
Time frame: Month 6
Change From Baseline to Months 1, 6, and 12 in OMERACT RAMRIS Wrist and MCP Synovitis
Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.
Time frame: Months 1, 6, and 12
Change From Baseline to Months 1, 3, and 12 in OMERACT RAMRIS Bone Marrow Edema in Wrist and MCP
Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0â€"3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1â€"33% of bone edematous; 2: 34â€"66% of bone edematous; 3: 67â€"100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.
Time frame: Months 1, 3, and 12
Change From Baseline to Months 1, 3, 6, and 12 in OMERACT RAMRIS Wrist and MCP Erosions
Bone erosion assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Each site was scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. OMERACT RAMRIS total erosion score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist is 250 (range 0-250). Increasing score=greater severity.
Time frame: Months 1, 3, 6, and 12
Modified Total Sharp Score (mTSS) at Months 6 and 12
Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) plus (+) erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Change From Baseline to Months 6 and 12 in mTSS
Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) + erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Joint Space Narrowing (JSN) Scores at Months 6 and 12
JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Change From Baseline to Months 6 and 12 in JSN Scores
JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Erosion Scores at Months 6 and 12
Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Change From Baseline to Months 6 and 12 in Erosion Score
Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
Time frame: Months 6 and 12
Percentage of Participants With an American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20) Response
ACR20 response: greater than or equal to (≥)20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Participant's Assessment of Pain; Participant's Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With an ACR 50% Improvement (ACR50) Response
ACR50 response: ≥ 50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of disease activity, 3) Paricipant's Assessment of Pain, 4) Participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With an ACR 70% Improvement (ACR70) Response
ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of Disease Activity, 3) Participant's Assessment of Pain, 4) Participant's Assessment of Functional Disability via a HAQ, and 5) CRP at each visit.
Time frame: Months 1, 2, 3, 6, 9, and 12
Disease Activity Score Based on 28-Joint Count and CRP (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (≤)3.2 implied low disease activity and greater than (\>)3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<)2.6 = remission.
Time frame: Baseline and Months 1, 2, 3, 6, 9, and 12
Change From Baseline in DAS28-3 (CRP)
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity.
Time frame: Months 1, 2, 3, 6, 9, and 12
Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-4 [ESR])
DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity. DAS28-4 (ESR) ≤3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
Time frame: Baseline and Months 1, 2, 3, 6, 9, and 12
Change From Baseline in DAS28-4 (ESR)
DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity.
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-3 (CRP) Response (Good or Moderate Improvement)
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from baseline \[BL\]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-3 (CRP) Score ≤3.2
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity.
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-3 (CRP) Score <2.6
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) \<2.6 implied remission.
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-4 (ESR) Response (Good or Moderate Improvement)
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-4 (ESR) ≤3.2
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity.
Time frame: Months 1, 2, 3, 6, 9, and 12
Percentage of Participants With DAS28-4 (ESR) <2.6
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) \<2.6 implied remission.
Time frame: Months 1, 2, 3, 6, 9, and 12
| Milestone | Tofacitinib (CP-690,550) Plus Methotrexate (MTX) | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Started | 36 | 36 | 37 |
| Completed | 28 | 27 | 21 |
| Not completed | 8 | 9 | 16 |
| Withdrew: Lack of efficacy | 0 | 0 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Adverse event | 4 | 2 | 5 |
| Withdrew: Reason not specified | 1 | 0 | 0 |
Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis | -0.80 ± 0.41 | -0.69 ± 0.40 | -0.17 ± 0.40 |
Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0-3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Change From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema | -1.26 ± 0.41 | -1.45 ± 0.42 | 0.29 ± 0.42 |
Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=28,31,35) | -0.42 ± 0.42 | -0.34 ± 0.40 | -0.17 ± 0.38 |
| Month 6 (n=33,29,28) | -1.22 ± 0.40 | -1.29 ± 0.41 | -0.28 ± 0.42 |
| Month 12 (n=29,26,21) | -2.26 ± 0.41 | -1.16 ± 0.43 | -0.66 ± 0.46 |
Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0â€"3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1â€"33% of bone edematous; 2: 34â€"66% of bone edematous; 3: 67â€"100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=28,31,35) | -0.29 ± 0.43 | 0.19 ± 0.41 | 0.11 ± 0.39 |
| Month 3 (n=30,32,31) | -0.77 ± 0.42 | -0.86 ± 0.41 | 0.47 ± 0.41 |
| Month 12 (n=29,26,21) | -1.52 ± 0.42 | -1.70 ± 0.43 | 0.59 ± 0.46 |
Bone erosion assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Each site was scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. OMERACT RAMRIS total erosion score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist is 250 (range 0-250). Increasing score=greater severity.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=28,31,35) | -0.12 ± 0.25 | 0.27 ± 0.25 | 0.27 ± 0.24 |
| Month 3 (n=30,32,31) | -0.12 ± 0.25 | 0.36 ± 0.24 | 0.44 ± 0.25 |
| Month 6 (n=33,29,28) | -0.06 ± 0.25 | -0.02 ± 0.25 | 0.65 ± 0.25 |
| Month 12 (n=29,26,21) | -0.11 ± 0.25 | -0.08 ± 0.25 | 1.18 ± 0.26 |
Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) plus (+) erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 11.28 ± 0.50 | 10.70 ± 0.51 | 11.77 ± 0.52 |
| Month 12 (n=26,25,22) | 11.70 ± 0.51 | 10.69 ± 0.52 | 12.21 ± 0.54 |
Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) + erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 0.44 ± 0.50 | -0.14 ± 0.51 | 0.93 ± 0.52 |
| Month 12 (n=26,25,22) | 0.85 ± 0.51 | -0.15 ± 0.52 | 1.36 ± 0.54 |
JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 5.45 ± 0.34 | 5.11 ± 0.35 | 5.52 ± 0.36 |
| Month 12 (n=26,25,22) | 5.59 ± 0.35 | 5.05 ± 0.36 | 5.88 ± 0.37 |
JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 0.29 ± 0.34 | -0.06 ± 0.35 | 0.35 ± 0.36 |
| Month 12 (n=26,25,22) | 0.43 ± 0.35 | -0.12 ± 0.36 | 0.71 ± 0.37 |
Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 5.84 ± 0.24 | 5.59 ± 0.25 | 6.26 ± 0.25 |
| Month 12 (n=26,25,22) | 6.10 ± 0.25 | 5.64 ± 0.26 | 6.33 ± 0.27 |
Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 6 (n=29,27,28) | 0.16 ± 0.24 | -0.10 ± 0.25 | 0.58 ± 0.25 |
| Month 12 (n=26,25,22) | 0.42 ± 0.25 | -0.05 ± 0.26 | 0.65 ± 0.27 |
ACR20 response: greater than or equal to (≥)20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Participant's Assessment of Pain; Participant's Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=35,35,37) | 42.86 | 57.14 | 29.73 |
| Month 2 (n=35,36,37) | 68.57 | 61.11 | 40.54 |
| Month 3 (n=35,36,37) | 77.14 | 61.11 | 48.65 |
| Month 6 (n=35,36,37) | 74.29 | 66.67 | 45.95 |
| Month 9 (n=35,36,37) | 71.43 | 58.33 | 43.24 |
| Month 12 (n=35,36,37) | 71.43 | 61.11 | 43.24 |
ACR50 response: ≥ 50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of disease activity, 3) Paricipant's Assessment of Pain, 4) Participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=35,35,37) | 22.86 | 22.86 | 2.70 |
| Month 2 (n=35,36,37) | 45.71 | 33.33 | 16.22 |
| Month 3 (n=35,36,37) | 48.57 | 50.00 | 24.32 |
| Month 6 (n=35,36,37) | 57.14 | 47.22 | 21.62 |
| Month 9 (n=35,36,37) | 57.14 | 44.44 | 29.73 |
| Month 12 (n=35,36,37) | 57.14 | 44.44 | 29.73 |
ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of Disease Activity, 3) Participant's Assessment of Pain, 4) Participant's Assessment of Functional Disability via a HAQ, and 5) CRP at each visit.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=35,35,37) | 8.57 | 2.86 | 0.00 |
| Month 2 (n=35,36,37) | 31.43 | 22.22 | 5.41 |
| Month 3 (n=35,36,37) | 25.71 | 27.78 | 10.81 |
| Month 6 (n=35,36,37) | 34.29 | 30.56 | 21.62 |
| Month 9 (n=35,36,37) | 31.43 | 33.33 | 18.92 |
| Month 12 (n=35,36,37) | 22.86 | 33.33 | 21.62 |
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (≤)3.2 implied low disease activity and greater than (\>)3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<)2.6 = remission.
| score on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Baseline (n=36,36,37) | 5.14 ± 0.96 | 5.48 ± 0.78 | 5.36 ± 0.80 |
| Month 1 (n=33,35,37) | 3.71 ± 1.15 | 4.03 ± 0.91 | 4.65 ± 1.07 |
| Month 2 (n=33,33,32) | 2.99 ± 1.17 | 3.52 ± 1.15 | 4.21 ± 1.31 |
| Month 3 (n=33,33,31) | 3.06 ± 1.02 | 3.46 ± 1.09 | 3.87 ± 1.43 |
| Month 6 (n=31,29,29) | 2.74 ± 1.15 | 2.75 ± 0.95 | 3.92 ± 1.49 |
| Month 9 (n=30,28,24) | 2.37 ± 0.98 | 2.85 ± 0.90 | 3.58 ± 1.63 |
| Month 12 (n=27,26,20) | 2.49 ± 1.02 | 2.68 ± 1.05 | 3.58 ± 1.40 |
DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=33,35,37) | -1.61 ± 0.19 | -1.40 ± 0.18 | -0.73 ± 0.18 |
| Month 2 (n=33,33,32) | -2.32 ± 0.19 | -1.88 ± 0.19 | -1.24 ± 0.19 |
| Month 3 (n=33,33,31) | -2.25 ± 0.19 | -1.96 ± 0.19 | -1.57 ± 0.19 |
| Month 6 (n=31,29,29) | -2.54 ± 0.19 | -2.55 ± 0.20 | -1.52 ± 0.19 |
| Month 9 (n=30,28,24) | -2.92 ± 0.20 | -2.43 ± 0.20 | -1.76 ± 0.21 |
| Month 12 (n=27,26,20) | -2.78 ± 0.20 | -2.61 ± 0.20 | -1.77 ± 0.22 |
DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity. DAS28-4 (ESR) ≤3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Baseline (n=36,36,37) | 6.25 ± 0.94 | 6.50 ± 0.75 | 6.44 ± 0.78 |
| Month 1 (n=34,35,37) | 4.60 ± 1.37 | 4.93 ± 1.12 | 5.51 ± 1.09 |
| Month 2 (n=32,33,31) | 3.77 ± 1.34 | 4.36 ± 1.40 | 5.05 ± 1.26 |
| Month 3 (n=33,33,31) | 3.66 ± 1.16 | 4.12 ± 1.31 | 4.63 ± 1.63 |
| Month 6 (n=30,29,28) | 3.32 ± 1.45 | 3.51 ± 1.20 | 4.75 ± 1.76 |
| Month 9 (n=30,28,24) | 3.06 ± 1.27 | 3.58 ± 1.10 | 4.17 ± 1.91 |
| Month 12 (n=27,26,20) | 3.02 ± 1.22 | 3.47 ± 1.36 | 4.13 ± 1.76 |
DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity.
| scores on a scale | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=34,35,37) | -1.77 ± 0.21 | -1.57 ± 0.21 | -0.94 ± 0.20 |
| Month 2 (n=32,33,31) | -2.59 ± 0.22 | -2.08 ± 0.21 | -1.41 ± 0.21 |
| Month 3 (n=33,33,31) | -2.69 ± 0.21 | -2.35 ± 0.21 | -1.80 ± 0.21 |
| Month 6 (n=30,29,28) | -3.02 ± 0.22 | -2.81 ± 0.22 | -1.73 ± 0.22 |
| Month 9 (n=30,28,24) | -3.29 ± 0.22 | -2.72 ± 0.22 | -2.14 ± 0.23 |
| Month 12 (n=27,26,20) | -3.31 ± 0.22 | -2.84 ± 0.22 | -2.18 ± 0.24 |
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from baseline \[BL\]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=33,35,37) | 75.76 | 71.43 | 43.24 |
| Month 2 (n=34,36,37) | 91.18 | 80.56 | 56.76 |
| Month 3 (n=34,36,37) | 91.18 | 77.78 | 56.76 |
| Month 6 (n=34,36,37) | 88.24 | 77.78 | 54.05 |
| Month 9 (n=34,36,37) | 79.41 | 69.44 | 45.95 |
| Month 12 (n=34,36,37) | 82.35 | 72.22 | 45.95 |
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=33,35,37) | 33.33 | 17.14 | 10.81 |
| Month 2 (n=34,36,37) | 50.00 | 36.11 | 21.62 |
| Month 3 (n=34,36,37) | 50.00 | 41.67 | 21.62 |
| Month 6 (n=34,36,37) | 61.76 | 55.56 | 27.03 |
| Month 9 (n=34,36,37) | 64.71 | 58.33 | 29.33 |
| Month 12 (n=34,36,37) | 61.76 | 50.00 | 27.03 |
DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) \<2.6 implied remission.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=33,35,37) | 18.18 | 5.71 | 5.41 |
| Month 2 (n=34,36,37) | 35.29 | 16.67 | 8.11 |
| Month 3 (n=34,36,37) | 32.35 | 22.22 | 13.51 |
| Month 6 (n=34,36,37) | 47.06 | 33.33 | 16.22 |
| Month 9 (n=34,36,37) | 50.00 | 38.89 | 18.92 |
| Month 12 (n=34,36,37) | 47.06 | 33.33 | 13.51 |
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=34,35,37) | 67.65 | 62.86 | 29.73 |
| Month 2 (n=32,33,31) | 85.29 | 69.44 | 59.46 |
| Month 3 (n=33,33,31) | 91.18 | 69.44 | 51.35 |
| Month 6 (n=30,29,28) | 85.29 | 77.78 | 51.35 |
| Month 9 (n=30,28,24) | 82.35 | 72.22 | 45.95 |
| Month 12 (n=27,26,20) | 79.41 | 69.44 | 45.95 |
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=34,35,37) | 20.59 | 8.57 | 2.70 |
| Month 2 (n=34,36,37) | 35.29 | 13.89 | 8.11 |
| Month 3 (n=34,36,37) | 32.35 | 30.56 | 13.51 |
| Month 6 (n=34,36,37) | 41.18 | 27.78 | 18.92 |
| Month 9 (n=34,36,37) | 44.12 | 33.33 | 18.92 |
| Month 12 (n=34,36,37) | 50.00 | 30.56 | 16.22 |
DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) \<2.6 implied remission.
| percentage of participants | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Month 1 (n=34,35,37) | 5.88 | 2.86 | 0.00 |
| Month 2 (n=34,36,37) | 17.65 | 5.56 | 2.70 |
| Month 3 (n=34,36,37) | 23.53 | 2.78 | 13.51 |
| Month 6 (n=34,36,37) | 29.41 | 13.89 | 13.51 |
| Month 9 (n=34,36,37) | 35.29 | 13.89 | 16.22 |
| Month 12 (n=34,36,37) | 32.35 | 19.44 | 13.51 |
Collected over Adverse events were collected up to 28 calendar days after the last administration of investigational product.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib (CP-690,550) Plus MTX | — | 2/36 (5.6%) | 24/36 (66.7%) |
| Tofacitinib (CP-690,550) | — | 1/36 (2.8%) | 31/36 (86.1%) |
| Methotrexate | — | 2/37 (5.4%) | 29/37 (78.4%) |
| Event | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Angina pectorisCardiac disorders | 0/36 | 1/36 | 0/37 |
| Anal abscessInfections and infestations | 1/36 | 0/36 | 0/37 |
| Foot deformityMusculoskeletal and connective tissue disorders | 1/36 | 0/36 | 0/37 |
| HematocheziaGastrointestinal disorders | 0/36 | 0/36 | 1/37 |
| CholelithiasisHepatobiliary disorders | 0/36 | 0/36 | 1/37 |
| Event | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 6/36 | 0/36 | 5/37 |
| HypertensionVascular disorders | 1/36 | 6/36 | 0/37 |
| GastritisGastrointestinal disorders | 0/36 | 5/36 | 4/37 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/36 | 2/36 | 5/37 |
| RashSkin and subcutaneous tissue disorders | 1/36 | 4/36 | 0/37 |
| BronchitisInfections and infestations | 3/36 | 0/36 | 0/37 |
| PharyngitisInfections and infestations | 2/36 | 3/36 | 2/37 |
| Upper respiratory tract infectionInfections and infestations | 3/36 | 2/36 | 2/37 |
| Blood creatine phosphokinase increasedInvestigations | 1/36 | 3/36 | 1/37 |
| HeadacheNervous system disorders | 3/36 | 2/36 | 2/37 |
Full Analysis Set (FAS): all participants who were randomized to study medication and received at least 1 dose of randomized study medication.
| Age, Continuous(years) | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate | Total |
|---|---|---|---|---|
| Mean | 47.8 ± 12.3 | 50.8 ± 12.8 | 47.8 ± 11.6 | 48.8 ± 12.2 |
| Sex: Female, Male(Participants) | Tofacitinib (CP-690,550) Plus MTX | Tofacitinib (CP-690,550) | Methotrexate | Total |
|---|---|---|---|---|
| Female | 31 | 30 | 29 | 90 |
| Male | 5 | 6 | 8 | 19 |
The record gives a start of Oct 2010, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tofacitinib · Methotrexate